Bicara Therapeutics (NASDAQ:BCAX) Issues Quarterly Earnings Results, Misses Estimates By $0.22 EPS

Bicara Therapeutics (NASDAQ:BCAX) posted its quarterly earnings results on Monday. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.22), FiscalAI reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Bicara said its pivotal FORTIFI-HN01 trial has reached substantial enrollment and still expects a top-line interim analysis in mid-2027. The company now plans to include an interim overall-survival analysis, but has not specified its timing or scope.
• Bicara highlighted phase I-B results for FICERA plus pembrolizumab in HPV-negative head and neck cancer: a 54% confirmed response rate, 25% complete response rate, median duration of response of nearly 22 months, and median overall survival just over 21 months. These are early-stage results; the pivotal trial remains blinded and will test whether the findings are confirmed.
• Recent results from a competitor have increased focus on the evolving treatment landscape and potential competition. Bicara argues that FICERA’s HPV-negative-only strategy and response depth could differentiate it, while acknowledging that survival maturity, subgroup outcomes, and regulatory paths remain uncertain.
• Bicara ended the quarter with about $442 million in cash, equivalents, and marketable securities, which it expects to fund operations into the first half of 2029, including the pivotal trial through final overall-survival analysis and launch preparations. Operating expenses rose year over year as the company advanced trials and expanded its organization.

Bicara Therapeutics Trading Up 9.9%

Shares of NASDAQ:BCAX traded up $1.00 during trading on Wednesday, hitting $11.19. 489,440 shares of the stock were exchanged, compared to its average volume of 757,184. The company has a fifty day moving average price of $17.63 and a two-hundred day moving average price of $20.88. The company has a market cap of $740.11 million, a PE ratio of -3.28 and a beta of -0.33. Bicara Therapeutics has a 12-month low of $7.87 and a 12-month high of $30.99.

Insiders Place Their Bets

In related news, CEO Ryan Cohlhepp sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total value of $400,750.00. Following the completion of the transaction, the chief executive officer directly owned 181,641 shares of the company’s stock, valued at $4,159,578.90. This trade represents a 8.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is owned by insiders.

More Bicara Therapeutics News

Investors following BCAX have been watching these news items:

• Neutral Sentiment: HC Wainwright, Morgan Stanley, Stifel Nicolaus and BTIG all lowered their BCAX price targets, but kept Buy or Overweight ratings. The revised targets remain well above the recently cited share price, though the cuts signal more cautious expectations.
• Negative Sentiment: Bicara’s latest reported quarterly loss was wider than analysts expected: earnings per share were -$1.04 versus a consensus estimate of -$0.82. This may weigh on sentiment as investors assess the company’s development costs and progress. Bicara Q3 2026 Earnings Call Transcript
• Neutral Sentiment: A report described short interest as having increased, but listed total short interest as zero shares. That inconsistency makes the data difficult to interpret as a reliable trading signal.

Wall Street Analysts Forecast Growth

BCAX has been the topic of several recent analyst reports. Wall Street Zen cut Bicara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 31st. Benchmark reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, October 29th. BMO Capital Markets assumed coverage on Bicara Therapeutics in a report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, October 2nd. Finally, HC Wainwright dropped their price objective on Bicara Therapeutics from $42.00 to $36.00 and set a “buy” rating on the stock in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.